glutamine has been researched along with Benign Monoclonal Gammopathies in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Accardi, F; Agnelli, L; Airoldi, I; Allegri, M; Andreoli, R; Aversa, F; Barilli, A; Bianchi, MG; Bolzoni, M; Bussolati, O; Cavalli, A; Chiu, M; Costa, F; Dall'Asta, V; Donofrio, G; Giuliani, N; Mancini, C; Marchica, V; Martella, E; Missale, G; Nicolini, F; Storti, P; Todoerti, K; Toscani, D; Vescovini, R | 1 |
1 other study(ies) available for glutamine and Benign Monoclonal Gammopathies
| Article | Year |
|---|---|
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Transport System ASC; Ammonium Compounds; Animals; Asparaginase; Biological Transport; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Glutamate-Ammonia Ligase; Glutaminase; Glutamine; Humans; Male; Membrane Transport Proteins; Mice, Inbred NOD; Mice, SCID; Middle Aged; Minor Histocompatibility Antigens; Molecular Targeted Therapy; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Syndecan-1 | 2016 |